APPROVED FOR THE TREATMENT OF IPF, SSc-ILD AND PF-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1

Rheum MTE – Management Strategies Key highlights -Dr. M. Aringer

Document ID: EM-MY-100194

30/06/2022

Author: Boehringer Ingelheim

RELATED CONTENT

 
EM-MY-100194
Production date: June 2022